Diligent Announces Shiza Shahid, Moisés Naím, Michael Montelongo, Veena Ramani and More to Deliver Impactful Sessions at the Fourth Annual Modern Governance Summit
14.9.2022 21:37:00 EEST | Business Wire | Press release
Diligent, the global leader in modern governance providing SaaS solutions across governance, risk, compliance, audit and ESG, today announced keynote speakers and agenda highlights for its annual Modern Governance Summit (MGS), taking place in Austin, Texas and online between September 12-14, 2022.
World-renowned leaders will take the stage to explore key issues like risk and strategy; ethics and compliance; environmental, social and corporate governance (ESG); digital transformation and more. Attendees will have the opportunity to network with peers and hear from industry experts in impactful sessions like “The World Hangs in the Balance: Getting ESG Right”; “Living Your Purpose: Putting Your Values and Ethics First in Business”; “The Evolving Risk Landscape – Implications of Geopolitical and Financial Risk”; “What Has Changed (and what hasn't) Since SOX”; and “The Courage to Lead: What it Takes to Build a Purpose-Driven Enterprise.” A full agenda can be found here.
Just a few of the inspirational speakers at this year’s MGS include:
- Shiza Shahid, an entrepreneur, investor, technologist, and impact leader, co-founded the Malala Fund with Nobel Prize winner Malala Yousafzai and led the organization as founding CEO. She is now the co-founder of Our Place, a mission-driven e-commerce startup that is creating products and telling stories that celebrate cultural traditions and reinvest in communities, through the lens of food and home-cooking. Shiza will deliver a session on putting values and ethics first in business.
- Moisés Naím, internationally syndicated columnist and best-selling author. In the early 1990s, Dr. Naím served as Venezuela’s Minister of Trade and Industry, as director of Venezuela’s Central Bank, and as executive director of the World Bank. Dr. Naím will be a keynote speaker discussing geopolitical risk and strategy.
- Sherron Watkins, former Vice President of Corporate Development at the Enron Corporation, whose exposure of corporate misconduct paved the way for the enactment of SOX corporate reform law. Sherron will be part of a panel discussion on what has changed – and what hasn’t – since Sarbanes-Oxley Act was enacted 20 years ago.
- Cynthia Cooper, accountant who formerly served as the Vice President of Internal Audit at WorldCom where her team exposed the largest accounting fraud in U.S. history. Cynthia will also be part of the panel on what has changed since SOX.
- The Honorable Michael Montelongo, President and CEO of GRC Advisory Services, LLC, and former Bush White House appointee who served as the 19th assistant secretary for financial management and CFO of the US Air Force and the first Latino in that role. Michael will join Cynthia Cooper and Sherron Watkins in the SOX panel discussion.
- Veena Ramani, Research Director at FCLTGlobal and expert in corporate governance, climate change and ESG issues. Veena will be part of panel discussions on preparing for shareholder and stakeholder ESG activism and getting ESG right.
- Enrique Acevedo, CBS Correspondent who has interviewed some of the world’s biggest leaders, including President Barack Obama, Melinda Gates, Kofi Annan and more. Enrique will moderate “The World Hangs in the Balance: Getting ESG Right.”
“Organizations today are navigating complex and ever-evolving business landscapes, where uncertainty is omnipresent,” said Brian Stafford, CEO of Diligent. “In this era, the role of governance, risk, compliance, audit and ESG professionals has become even more critical. We’re honored to be engaging with this community of leaders in person once again as we explore the intersection of performance, risk and purpose, and to welcome this year’s roster of world-renowned speakers.”
Now in its fourth year, the Modern Governance Summit is the largest governance, risk and compliance (GRC) event of the year bringing together thousands of leaders from board members to corporate secretaries, general counsels, chief compliance officers and other governance professionals. Designed to elevate GRC practices and explore key issues facing organizations today, attendees benefit from 2.5 days of thought leadership, networking and product training opportunities.
The event is open to the press and most sessions will be on the record. For more information and to register contact: press@diligent.com
About Diligent
Diligent is the global leader in modern governance, providing SaaS solutions across governance, risk, compliance, audit and ESG. Serving more than 1 million users from over 25,000 customers around the world, we empower transformational leaders with software, insights and confidence to drive greater impact and lead with purpose. Learn more at diligent.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005247/en/
Contact information
Media Contact
Julia Hanbury
Senior Communications Manager, Diligent
+1-604-669-4225
Jhanbury@diligent.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
